Standard treatments induce antigen-specific immune responses in prostate cancer

Clinical Cancer Research

Volumn 13, Issue 5, 2007, Pages 1493-1502

  Nesslinger, Nancy J ^a   Sahota, Robert A ^a   Stone, Brad ^b   Johnson, Kayli ^a   Chima, Navraj ^a   King, Caitlin ^a   Rasmussen, Devon ^a   Bishop, Darcy ^a   Rennie, Paul S ^c   Gleave, Martin ^c   Blood, Paul ^a   Pai, Howard ^b   Ludgate, Charles ^a   Nelson, Brad H ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATPASE FAMILY AAA DOMAIN CONTAINING 3A; AUTOANTIBODY; CELLULAR SENESCENCE INHIBITED GENE PROTEIN; CENTROSOMAL PROTEIN 78; COMPLEMENTARY DNA; DIHYDROLIPOAMIDE DEHYDROGENASE; F BOX ONLY PROTEIN 38; HORMONE; KINECTIN; OUTER DENSE FIBER OF SPERM TAILS 2; PEROXISOMAL D3,D2 EONYL COA ISOMERASE; PHD FINGER PROTEIN 20; POLY(ADP RIBOSE)POLYMERASE FAMILY MEMBER 1; RA1A BINDING PROTEIN 1; RECOMBINING BINDING PROTEIN SUPPRESSOR OF HAIRLESS; SEROLOGICALLY DEFINED COLON CANCER ANTIGEN; SON DNA BINDING PROTEIN; SWITCH ASSOCIATED PROTEIN; SYNAPTONEMAL COMPLEX PROTEIN 65; TUMOR PROTEIN; UBIQUITIN SPECIFIC PROTEASE 11; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN 707;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CELL INFILTRATION; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; T LYMPHOCYTE; TUMOR IMMUNITY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, HORMONAL; AUTOANTIBODIES; BLOTTING, WESTERN; BRACHYTHERAPY; GENE LIBRARY; HUMANS; MALE; MICE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 33947374421     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1772     Document Type: Article

References (82)

1. McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 2000;164: 1825-9.
2. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98:14565-70.
3. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58: 3491-4.
4. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-6.
5. Marrogi AJ, Munshi A, Merogi AJ, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma. Int J Cancer 1997;74:492-501.
6. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer [comment]. N Engl J Med 2003;348: 203-13.
7. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.
8. Troy A, Davidson P, Atkinson C, Hart D. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer [comment]. J Urol 1998;160:214-9.
9. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000; 60:5857-61.
10. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30A:1797-803.
11. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53: 109-17.
12. Cavacini LA, Duval M, Eder JP, Posner MR. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. Clin Cancer Res 2002;8:368-73.
13. Tjoa BA, Lodge PA, Salgaller ML, Boynton AL, Murphy GP. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin 1999;49: 117-28, 65.
14. Valone FH, Small E, MacKenzie M, et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J 2001;7:S53-61.
15. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62.
16. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells [comment]. J Clin Oncol 2000; 18:3894-903.
17. Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 2006;24: 434-41.
18. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
19. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 2005;23:8262-9.
20. Leitner WW, Restifo NP. DNA vaccines and apoptosis: to kill or not to kill? J Clin Invest 2003;112: 22-4.
21. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765-80.
22. McBride WH, Chiang CS, Olson JL, et al. A sense of danger from radiation. Radiat Res 2004; 162:1-19.
23. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005;63:655-66.
24. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000;407:784-8.
25. Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004;173:6098-108.
26. Stone B, Schummer M, Paley RJ, et al. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer 2003; 104:73-84.
27. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
28. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60:170-6.
29. Akakura K, Bruchovsky N, Rennie PS, et al. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol 1996;59:501-11.
30. Rennie PS, Bruchovsky N, Coldman AJ. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J Steroid Biochem Mol Biol 1990;37:843-7.
31. So AI, Bowden M, Gleave M. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours. BJU Int 2004;93:845-50.
32. Rennie PS, Bruchovsky N, Buttyan R, Benson M, Cheng H. Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res 1988;48: 6309-12.
33. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 2004;53:139-43.
34. Hoeppner LH, Dubovsky JA, Dunphy EJ, McNeel DG. Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun 2006;6:1.
35. Jager D, Karbach J, Pauligk C, et al. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun 2005;5:11.
36. Zhou Y, Toth M, Hamman MS, et al. Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. Biochem Biophys Res Commun 2002;290: 830-8.
37. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-8.
38. Nickenig G, Wolff M, Stablein A, Pfister H, Bohm M. Enhanced expression and autoimmunity of recombination signal binding protein-jκ in human dilated cardiomyopathy. Biochem Biophys Res Commun 1999;266:432-6.
39. Scanlan MJ, Chen YT, Williamson B, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76: 652-8.
40. Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987; 69:557-65.
41. Rajczy K, Vargha P, Beregi E. Relationship between immunoglobulin levels and specific antibody titers in the elderly. Z Gerontol 1986;19:158-61.
42. Candore G, Di Lorenzo G, Mansueto P, et al. Prevalence of organ-specific and non organ-specific autoantibodies in healthy centenarians. Mech Ageing Dev 1997;94:183-90.
43. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993;118:793-803.
44. Comtesse N, Zippel A, Walle S, et al. Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A 2005;102:9601-6.
45. Wang Y, Han KJ, Pang XW, et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 2002;169:1102-9.
46. Wu YY, Hsu TC, Chen TY, et al. Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection. Clin Exp Immunol 2002;128:347-52.
47. Wang HC, Su YR, Han KJ, et al. Multiple variants and a differential splicing pattern of kinectin in human hepatocellular carcinoma. Biochem Cell Biol 2004;82: 321-7.
48. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [comment]. Lancet 2002;360:103-6.
49. Ludgate CM, Lim JT, Wilson AG, Alexander AS, Wilson KS. Neoadjuvant hormone therapy and external beam radiation for localized prostate cancer: Vancouver Island Cancer Centre experience. Can J Urol 2000;7:937-43.
50. Wadle A, Mischo A, Imig J, et al. Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library. Int J Cancer 2005;117:104-13.
51. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000;37:1141-9.
52. Nakada T, Noguchi Y, Satoh S, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003;3:10.
53. Dunphy EJ, McNeel DG. Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand. J Immunother 2005;28:268-75.
54. Fossa A, Alsoe L, Crameri R, Funderud S, Gaudernack G, Smeland EB. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 2004;53:431-8.
55. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353:1224-35.
56. Isaacs JT, Furuya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 1994;5:391-400.
57. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47.
58. Rosen A, Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999;6:6-12.
59. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A 2001;98:12659-64.
60. Casiano CA, Ochs RL, Tan EM. Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. Cell Death Differ 1998;5:183-90.
61. Lim Y, Lee DY, Lee S, et al. Identification of autoantibodies associated with systemic lupus erythematosus. Biochem Biophys Res Commun 2002;295: 119-24.
62. Decker P, Isenberg D, Muller S. Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. J Biol Chem 2000;275:9043-6.
63. Winter SF, Sekido Y, Minna JD, et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 1993;85:2012-8.
64. Bergquist M, Brattstrom D, Larsson A, et al. p53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anticancer Res 1998;18:1999-2002.
65. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60:1777-88.
66. Lim PL, Zouali M. Pathogenic autoantibodies: emerging insights into tissue injury. Immunol Lett 2006;103:17-26.
67. Sisto M, Lisi S, Castellana D, et al. Autoantibodies from Sjogren's syndrome induce activation of both the intrinsic and extrinsic apoptotic pathways in human salivary gland cell line A-253. J Autoimmun 2006;27:38-49.
68. Hoffmann TK, Donnenberg AD, Finkelstein SD, et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 2002;62:3521-9.
69. van Rhee F, Szmania SM, Zhan F, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005;105:3939-44.
70. Crane IJ, Forrester JV. Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 2005;25: 75-102.
71. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354: 709-18.
72. Figdor CG, deVries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
73. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58:862-70.
74. Chi KH, Liu SJ, Li CP, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005;28:129-35.
75. Correale P, Cusi MG, Tsang KY, et al. Chemoimmunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005;23:8950-8.
76. Ochs RL, Stein TW, Jr., Chan EK, Ruutu M, Tan EM. cDNA cloning and characterization of a novel nucleolar protein. Mol Biol Cell 1996;7:1015-24.
77. Comtesse N, Heckel D, Maldener E, Glass B, Meese E. Probing the human natural autoantibody repertoire using an immunoscreening approach. Clin Exp Immunol 2000;121:430-6.
78. Geuijen CA, Bijl N, Smit RC, et al. A proteomic approach to tumour target identification using phage display, affinity purification and mass spectrometry. Eur J Cancer 2005;41:178-87.
79. Line A, Slucka Z, Stengrevics A, Silina K, Li G, Rees RC. Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol Immunother 2002;51: 574-82.
80. Struss AK, Romeike BF, Munnia A, et al. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme. Oncogene 2001;20: 4107-14.
81. Lu Y, Ye P, Chen SL, Tan EM, Chan EK. Identification of kinectin as a novel Behcet's disease autoantigen. Arthritis Res Ther 2005;7:R1133-9.
82. Hirano N, Butler MO, Von Bergwelt-Baildon MS, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003;102:4567-75.